Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 16/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313709 | 0.95 | FGFR3 (0.54) | FGFR3CYP11B1CYP11B2 | |
| SCHEMBL3316356 | 0.91 | FGFR3 (0.50) | FGFR3CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL3313560 | 0.91 | FGFR3 (0.51) | FGFR3CYP11B1CYP11B2 | |
| SCHEMBL3313707 | 0.88 | FGFR3 (0.54) | FGFR3CYP11B1CYP11B2 | |
| SCHEMBL1126473 | 0.84 | FGFR3 (0.72) | FGFR3 | |
| SCHEMBL3314125 | 0.83 | FGFR3 (0.72) | FGFR3 | |
| SCHEMBL3313556 | 0.82 | FGFR3 (0.51) | FGFR3CYP11B1CYP11B2 | |
| SCHEMBL3318311 | 0.80 | FGFR3 (0.73) | FGFR3 | |
| SCHEMBL17023170 | 0.80 | FGFR3 (0.56) | FGFR3CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL3317627 | 0.80 | FGFR3 (0.60) | FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | ABL1, NQO2, MAP4K5 | FGFR3 1515/4885CYP11B1 510/4885CYP11B2 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.